Fresenius Medical Care (NYSE:FMS) Shares Gap Up – Should You Buy?

Fresenius Medical Care AG (NYSE:FMS)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $23.17, but opened at $24.22. Fresenius Medical Care shares last traded at $24.23, with a volume of 53,280 shares.

Wall Street Analysts Forecast Growth

FMS has been the subject of a number of recent research reports. Berenberg Bank began coverage on Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 price objective for the company. Bank of America upgraded Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Friday, January 3rd. They issued a “strong-buy” rating for the company. Finally, Truist Financial boosted their price target on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th.

Fresenius Medical Care Stock Up 4.7 %

The business has a fifty day moving average price of $22.82 and a two-hundred day moving average price of $20.98. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42. The company has a market cap of $14.24 billion, a price-to-earnings ratio of 20.04, a P/E/G ratio of 0.75 and a beta of 0.92.

Fresenius Medical Care (NYSE:FMS) last released its earnings results on Tuesday, November 5th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.36 billion. During the same quarter in the prior year, the firm earned $0.31 EPS. On average, equities analysts predict that Fresenius Medical Care AG will post 1.53 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care

Large investors have recently added to or reduced their stakes in the business. Blue Trust Inc. boosted its stake in shares of Fresenius Medical Care by 15.6% during the 4th quarter. Blue Trust Inc. now owns 14,876 shares of the company’s stock worth $317,000 after acquiring an additional 2,013 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Fresenius Medical Care by 2.2% in the 4th quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company’s stock worth $1,456,000 after purchasing an additional 1,398 shares during the last quarter. Franklin Street Advisors Inc. NC bought a new stake in Fresenius Medical Care during the fourth quarter worth approximately $201,000. GAMMA Investing LLC grew its holdings in Fresenius Medical Care by 43.3% during the fourth quarter. GAMMA Investing LLC now owns 7,164 shares of the company’s stock valued at $162,000 after purchasing an additional 2,166 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Fresenius Medical Care by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after purchasing an additional 1,528 shares during the period. 8.37% of the stock is owned by institutional investors.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.